Skip to main content
Oxford Research Peptides
RESEARCH PRIMER

What is Semaglutide?

A concise, evidence-based introduction to Semaglutide — a long-acting GLP-1 receptor agonist derived from native GLP-1(7-37) and studied extensively in the metabolic, cardiovascular and renal literature.

QUICK ANSWER
TL;DR

Quick answer

Semaglutide is a synthetic long-acting agonist of the GLP-1 receptor. It shares the core GLP-1(7-37) sequence with three key modifications — Aib8, Arg34 and lysine-26 acylation with a C18 fatty-di-acid via a γGlu-2xOEG spacer — which extend its plasma half-life to roughly one week and allow once-weekly subcutaneous or once-daily oral dosing in humans.
EXTENDED ANSWER
AI-ready

Extended answer

What is Semaglutide?

Semaglutide is a synthetic long-acting glucagon-like peptide-1 (GLP-1) receptor agonist first described in the peer-reviewed literature by Lau and colleagues in 2015. It is derived from the native human incretin GLP-1(7-37) with three targeted modifications: α-aminoisobutyric acid at position 8 (Aib8) to resist DPP-4 cleavage, arginine at position 34 (Arg34) to enable regioselective acylation, and a C18 fatty-di-acid attached at lysine-26 through a γGlu-2xOEG spacer that supports reversible binding to serum albumin. Together these changes extend plasma half-life to approximately one week in humans. Semaglutide selectively agonises the GLP-1 receptor, a class B G-protein-coupled receptor, and is one of the most extensively studied compounds in the GLP-1 class. Oxford Research Peptides supplies Semaglutide as a lyophilised reference standard for in-vitro laboratory research only.
KEY FACTS

Key facts

Compound
Semaglutide
Target
GLP-1R (class B GPCR)
Class
Long-acting GLP-1 receptor agonist
Half-life
≈ 1 week (human, subcutaneous)

Definition and origin

Semaglutide is a synthetic peptide first described in the peer-reviewed literature by Lau and colleagues in 2015 as a once-weekly GLP-1 analogue.[1] It was designed from native human glucagon-like peptide-1 (GLP-1) with a small number of targeted modifications that dramatically extend its persistence in circulation without fundamentally changing its receptor pharmacology.[2]

Where GLP-1 comes from

Native GLP-1 is an incretin: a gut-derived peptide hormone released from intestinal L-cells in response to nutrient intake. It amplifies glucose-dependent insulin secretion from pancreatic β-cells, suppresses glucagon release from α-cells and slows gastric emptying — collectively known as the incretin effect.[4][3]

How Semaglutide differs from native GLP-1

  • Aib8: replacement of alanine at position 8 with α-aminoisobutyric acid confers resistance to dipeptidyl peptidase-4 (DPP-4), the enzyme that cleaves native GLP-1 within minutes.[1]
  • Arg34: substitution to prevent side-chain interference during synthesis of the acylated lysine.
  • Lys26 acylation: a C18 fatty-di-acid attached through a γGlu-2xOEG spacer supports reversible non-covalent binding to serum albumin, dramatically extending plasma residence.[2]

What receptor does Semaglutide act at?

Semaglutide is a selective agonist of the GLP-1 receptor (GLP-1R), a class B (secretin-family) G-protein-coupled receptor.[10] It does not activate the GIP or glucagon receptors at pharmacologically meaningful concentrations, distinguishing it from dual-agonist peptides such as Tirzepatide and triple-agonist peptides such as Retatrutide.

Research context

Semaglutide has been evaluated in one of the largest published GLP-1 receptor agonist evidence bases, including SUSTAIN-6 in type 2 diabetes,[5] STEP-1 in overweight and obesity,[6] SELECT in obesity without diabetes,[7] PIONEER 6 for oral Semaglutide[8] and FLOW in chronic kidney disease with type 2 diabetes.[12]

Research-use framing

Approved Semaglutide medicines are prescription therapeutics regulated by the MHRA in the United Kingdom. Oxford Research Peptides supplies Semaglutide strictly as a lyophilised reference standard for in-vitro laboratory research. See Research Use Only and Testing & Quality Control for the framework applied to research-grade material.

Continue reading: Semaglutide mechanism of action, GLP-1 receptor explained, Triple agonists explained, Semaglutide monograph and the Semaglutide FAQ.

References12

  1. 1.

    Lau J, Bloch P, Schäffer L, et al.. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide.. Journal of Medicinal Chemistry. 2015;58(18):7370-7380.

    DOI: 10.1021/acs.jmedchem.5b00726PMID: 26308095
  2. 2.

    Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide.. Frontiers in Endocrinology. 2019;10:155.

    DOI: 10.3389/fendo.2019.00155PMID: 31031702
  3. 3.

    Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1.. Cell Metabolism. 2018;27(4):740-756.

    DOI: 10.1016/j.cmet.2018.03.001PMID: 29617641
  4. 4.

    Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP.. Gastroenterology. 2007;132(6):2131-2157.

    DOI: 10.1053/j.gastro.2007.03.054PMID: 17498508
  5. 5.

    Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6).. New England Journal of Medicine. 2016;375(19):1834-1844.

    DOI: 10.1056/NEJMoa1607141PMID: 27633186
  6. 6.

    Wilding JPH, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity (STEP 1).. New England Journal of Medicine. 2021;384(11):989-1002.

    DOI: 10.1056/NEJMoa2032183PMID: 33567185
  7. 7.

    Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT).. New England Journal of Medicine. 2023;389(24):2221-2232.

    DOI: 10.1056/NEJMoa2307563PMID: 37952131
  8. 8.

    Husain M, Birkenfeld AL, Donsmark M, et al.. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes (PIONEER 6).. New England Journal of Medicine. 2019;381(9):841-851.

    DOI: 10.1056/NEJMoa1901118PMID: 31185157
  9. 9.

    Buckley ST, Bækdal TA, Vegge A, et al.. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist.. Science Translational Medicine. 2018;10(467):eaar7047.

    DOI: 10.1126/scitranslmed.aar7047PMID: 30429357
  10. 10.

    de Graaf C, Donnelly D, Wootten D, et al.. Glucagon-like peptide-1 and its class B G protein–coupled receptors.. Pharmacological Reviews. 2016;68(4):954-1013.

    DOI: 10.1124/pr.115.011395PMID: 27736833
  11. 11.

    Gabery S, Salinas CG, Paulsen SJ, et al.. Semaglutide lowers body weight in rodents via distributed neural pathways.. JCI Insight. 2020;5(6):e133429.

    DOI: 10.1172/jci.insight.133429PMID: 32213703
  12. 12.

    Perkovic V, Tuttle KR, Rossing P, et al.. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW).. New England Journal of Medicine. 2024;391(2):109-121.

    DOI: 10.1056/NEJMoa2403347PMID: 38785209
EVIDENCE SUMMARY
Evidence

Evidence summary

Strong evidence
Research confidenceHigh confidence
Semaglutide's identity, structure and receptor selectivity are established in the peer-reviewed literature. Its efficacy and safety have been evaluated in large randomised clinical trials across metabolic, cardiovascular and renal endpoints.
RELATED GUIDES
COMPOUND REFERENCE
EDITORIAL NOTICE

Research use only

All materials referenced are supplied strictly for in-vitro laboratory research. Not for human or animal consumption, diagnosis, or therapeutic use.
VERSION HISTORY
Editorial Team
Oxford Research Peptides Editorial Team
In-house editorial staff
Oxford Research Peptides
Scientific Reviewer
Scientific Review Panel
Independent scientific review
Oxford Research Peptides

Publication information

Published
2026-09-02
Updated
2026-09-02
Reviewed
2026-09-02
Version
1.0

Revision history

  1. v1.02026-09-02· Editorial Team

    Initial publication of the Semaglutide cornerstone cluster (Authority Sprint 2B, Wave 1).

Editorial standards

Content is reviewed against our editorial process for scientific accuracy, sourcing, and clarity. Read our editorial standards.

Conflict of interest

Oxford Research Peptides supplies research-grade reference peptides commercially. Editorial pages are drafted and reviewed to describe published scientific literature accurately and do not recommend, promote or endorse any specific commercial product. Product mentions on educational pages are strictly for cross-referencing catalogue entries.

Next scheduled review: 2028-03-02. Our research methodology describes how the review is conducted.

Research use only

All materials referenced are supplied strictly for in-vitro laboratory research. Not for human or animal consumption, diagnosis, or therapeutic use.
Published: 2026-09-02Updated: 2026-09-02